Understanding Abnormal Signals in Acute Myeloid Leukemia
ABERRANT SIGNALING IN ACUTE MYELOID LEUKEMIA
['FUNDING_R01'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-11125969
This project explores new ways to stop abnormal signals in acute myeloid leukemia cells, aiming to find better treatments for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11125969 on ClinicalTrials.gov |
What this research studies
Acute myeloid leukemia (AML) can be hard to treat, and current therapies don't always work well, often due to chemotherapy resistance. This project looks at how certain genes cause AML and how we might block these harmful signals. Researchers have found that a protein called MYB works with another protein, CBP, to drive the disease. They are testing special inhibitors that can break apart these harmful protein interactions, which have shown promise in lab models. The goal is to develop new and more effective treatments for AML patients by dismantling these specific leukemia-causing complexes.
Who could benefit from this research
Good fit: Patients with acute myeloid leukemia, particularly those whose disease involves specific gene mutations or resistance to current chemotherapy, might eventually benefit from this research.
Not a fit: Patients with other types of leukemia or cancers not related to the specific signaling pathways targeted in AML may not directly benefit from this particular research.
Why it matters
Potential benefit: If successful, this work could lead to new, more effective treatments for acute myeloid leukemia that overcome chemotherapy resistance.
How similar studies have performed: While the specific peptidomimetic inhibitors are novel, the concept of targeting aberrant transcriptional complexes in cancer has been explored in other contexts with varying success.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KENTSIS, ALEX — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: KENTSIS, ALEX
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.